UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended October 31, 2003

 

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT

 

For the transition period from               to              

 

Commission file number 000-29278

 

KMG CHEMICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

10611 Harwin Drive, Suite 402
Houston, Texas 77036

(Address of principal executive offices)

 

(713) 988-9252

(Registrant’s telephone number including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ý       No o

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).  Yes o       No ý

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 

Indicate by check mark whether the registrant filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

 

Yes o       No o

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 7,550,019 shares of common stock.

 

 

Part I. — FINANCIAL INFORMATION

 

KMG CHEMICALS, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

		October 31, 2003			July 31, 2003
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	4,214,351		$	1,490,357
Marketable securities		0			164,735
Accounts receivable:
Trade		3,981,528			7,397,654
Other		215,132			352,962
Notes receivable - current portion		110,329			98,442
Inventories		4,995,915			5,285,870
Prepaid expenses and other current assets		202,231			178,573
Total current assets		13,719,486			14,968,593
PROPERTY, PLANT AND EQUIPMENT -
Net of accumulated depreciation		5,346,261			5,487,304
NOTES RECEIVABLE, Less current portion		34,992			65,844
DEFERRED TAX ASSET		551,052			510,929
INTANGIBLE ASSETS, net of accumulated amortization		10,280,735			10,397,761
OTHER ASSETS		1,164,896			907,079
TOTAL		$	31,097,422		$	32,337,510

 

2

 

 

KMG CHEMICALS, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

		October 31, 2003			July 31, 2003
LIABILITIES & STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable		$	2,397,327		$	3,388,311
Accrued liabilities		1,003,251			1,165,071
Current portion of long-term debt		504,996			504,996
Total current liabilities		3,905,574			5,058,378
LONG-TERM DEBT		4,124,174			4,250,423
Total liabilities		8,029,748			9,308,801
STOCKHOLDERS’ EQUITY
Preferred stock, $.01 par value, 10,000,000 shares authorized, none issued
Common stock, $.01 par value, 40,000,000 shares authorized, 7,730,019 shares issued and 7,550,019 shares outstanding at October 31, 2003 and 7,692,981 issued and 7,512,981 shares outstanding at July 31, 2003		77,301			76,930
Additional paid-in capital		3,372,880			3,365,976
Treasury stock		(900,000		)	(900,000		)
Accumulated other comprehensive income		11,577			73,753
Retained earnings		20,505,916			20,412,050
Total stockholders’ equity		23,067,674			23,028,709
TOTAL		$	31,097,422		$	32,337,510

 

See notes to consolidated financial statements.

 

3

 

KMG CHEMICALS, INC.

CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

 

		Three Months Ended October 31,
		2003			2002
NET SALES		$	8,372,110		$	8,053,629
COST OF SALES		5,825,906			5,337,278
Gross profit		2,546,204			2,716,351
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		2,077,764			1,986,607
Operating income		468,440			729,744
OTHER INCOME (EXPENSE):
Interest and dividend income		9,454			11,411
Interest expense		(60,595		)	(16,566		)
Gain on sale of securities		114,829
Other		(17,199		)	6,568
Total other income (expense)		46,489			1,413
INCOME BEFORE INCOME TAX		514,929			731,157
Provision for income tax		(195,673		)	(248,594		)
NET INCOME		$	319,256		$	482,564
EARNINGS PER SHARE:
Basic		$	0.04		$	0.06
Diluted		$	0.04		$	0.06
WEIGHTED AVERAGE SHARES OUTSTANDING:
Basic		7,523,448			7,512,981
Diluted		7,533,938			7,551,367

 

See notes to consolidated financial statements.

 

4

 

KMG CHEMICALS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

							ADDITIONAL PAID-IN CAPITAL			TREASURY STOCK			ACCUMULATED OTHER COMPREHENSIVE INCOME			RETAINED EARNINGS			TOTAL STOCKHOLDERS’ EQUITY
		COMMON STOCK
		SHARES ISSUED		PAR VALUE
BALANCE AT JULY 31, 2001		7,681,981		$	76,820		$	3,363,952		$	(900,000	)	$	211,480		$	16,523,861		$	19,276,113
Employee options exercised		11,000		110			2,024												2,134
Cash dividends																(319,083		)	(319,083		)
Net income																2,684,537			2,684,537
Change in unrealized gain on available for sale securities (net of taxes of $54,198)													(123,051		)				(123,051		)
BALANCE AT JULY 31, 2002		7,692,981		76,930			3,365,976			(900,000		)	88,429			18,889,315			21,520,650
Cash dividends																(394,429		)	(394,429		)
Net income																1,917,164			1,917,164
Change in unrealized gain on available for sale securities (net of taxes of $31,567)													(18,199		)				(18,199		)
Unrealized loss on interest rate swap (net of taxes of $24,654)													3,523						3,523
BALANCE AT JULY 31, 2003		7,692,981		76,930			3,365,976			(900,000		)	73,753			20,412,050			23,028,709
Cash dividends																(225,390		)	(225,390		)
Employee options exercised		37,038		371			6,904												7,275
Net income																319,256			319,256
Change in unrealized gain on available for sale securities due to sale of stock during quarter													(70,230		)				(70,230		)
Unrealized loss on interest rate swap (net of taxes of $4,530)													8,054						8,054
BALANCE AT OCTOBER 31, 2003		7,730,019		$	77,301		$	3,372,880		$	(900,000	)	$	11,577		$	20,505,916		$	23,067,674

 

See notes to consolidated financial statements.

 

5

 

KMG CHEMICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

		Three Months Ended October 31,
		2003			2002
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	319,256		$	482,564
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		363,547			344,199
Bad debt expense		10,000			15,000
Gain on sale of equipment		(187		)	(18,500		)
Gain on sale of securities		(114,829		)
Forgiveness of notes receivable from related parties					8,545
Deferred income taxes		(2,103		)	(160,591		)
Changes in operating assets and liabilities:
Accounts receivable - trade		3,406,126			3,459,214
Accounts receivable - other		137,830			37,846
Inventories		289,954			(238,310		)
Prepaid expenses and other assets		(23,657		)	127,907
Accounts payable		(990,984		)	(32,015		)
Accrued liabilities		(161,820		)	(389,793		)
Net cash provided by operating activities		3,233,133			3,636,066
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property, plant and equipment		(109,730		)	(22,272		)
Proceeds from sale of equipment		187			18,500
Proceeds from sale of securities		169,830
Notes receivable		18,965
Additions to other assets		(244,027		)	(263,311		)
Net cash used in investing activities		(164,775		)	(267,083		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on borrowings		(126,249		)	(1,462,652		)
Proceeds from exercise of stock options		7,275
Payment of dividends		(225,390		)	(169,041		)
Net cash used in financing activities		(344,364		)	(1,631,693		)
NET INCREASE IN CASH AND CASH EQUIVALENTS		2,723,994			1,737,290
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		1,490,357			1,234,581
CASH AND CASH EQUIVALENTS AT END OF PERIOD		$	4,214,351		$	2,971,872
SUPPLEMENTAL DISCLOSURES FOR CASH FLOW INFORMATION:
Cash paid during the period for interest		$	60,129		$	16,566
Cash paid during the period for income taxes		$	259,030		$	201,492

 

See notes to consolidated financial statements.

 

6

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

(1)                                  Basis of Presentation - The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in the opinion of management reflect all adjustments, including those of a normal recurring nature, that are necessary for a fair presentation of financial position and results of operations for the interim periods presented. These financial statements include the accounts of KMG Chemicals, Inc. and its subsidiaries (the “Company”). All significant intercompany balances and transactions have been eliminated in consolidation.  The condensed consolidated financial statements have been prepared pursuant to the requirements of the SEC for interim reporting.  As permitted under those requirements, certain footnotes or other financial information that are normally required by GAAP (accounting principles generally accepted in the United States of America) have been condensed or omitted.  The financial statements included herein should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended July 31, 2003.

 

(2)                                  Earnings Per Share - Basic earnings per share has been computed by dividing net income by the weighted average shares outstanding.  Diluted earnings per share has been computed by dividing net income by the weighted average shares outstanding plus dilutive potential common shares.

 

The following table presents information necessary to calculate basic and diluted earnings per share for periods indicated:

 

		Three Months Ended October 31
		2003			2002
BASIC EARNINGS PER SHARE
Net Income		$	319,256		$	482,564
Weighted Average Shares Outstanding		7,523,448			7,512,981
Basic Earnings Per Share		$	0.04		$	0.06
DILUTED EARNINGS PER SHARE
Net Income		$	319,256		$	482,564
Weighted Average Shares Outstanding		7,523,448			7,512,981
Shares Issuable from Assumed Conversion of Common Share Options		10,490			38,386
Weighted Average Shares Outstanding, as Adjusted		7,533,938			7,551,367
Diluted Earnings Per Share		$	0.04		$	0.06

 

7

 

(3)                                  Inventories- Inventories are summarized as follows:

 

		October 31, 2003			July 31, 2003
Chemical raw materials and supplies		$	832,655		$	827,292
Finished chemical products		4,163,260			4,458,578
		$	4,995,915		$	5,285,870

 

(4)                                  Intangible and Other Assets- Intangible and other assets are summarized as follows:

 

		October 31, 2003			July 31, 2003
Intangible assets consisted of the following:
Unamortized intangible assets:
Creosote sales and distribution assets		$	4,500,000		$	4,500,000
Other creosote related assets		77,604			77,604
Rabon product registrations and related assets		3,557,042			3,557,042
		8,134,646			8,134,646
Amortized intangible assets:
Creosote supply contract		4,000,000			4,000,000
MSMA product registrations and related assets		1,200,000			1,200,000
Other MSMA related assets		97,652			101,904
Licensing agreement		320,000			320,000
Other Rabon related assets		204,000			204,000
Loan Costs		42,985			42,985
		5,864,637			5,868,889
Total intangible assets		13,999,283			14,003,535
Less accumulated amortization		(3,718,548		)	(3,605,774		)
		$	10,280,735		$	10,397,761
Other assets consisted of the following:
Advances for premiums on employee-owned life insurance policies		555,426			521,740
Other		609,470			385,339
		$	1,164,896		$	907,079

 

Amortization expense was $112,775 and $102,298 for the three months ended October 31, 2003 and 2002, respectively.

 

8

 

(5)                                 Stock-based Compensation- The pro forma effect on net earnings and earnings per share if the Company had applied the fair value recognition provision of Statement of Financial Accounting Standards (SFAS) No. 123, “Accounting for Stock-based Compensation” (FAS 123), to stock-based employee compensation for the three months ended October 31, 2003 and 2002 is illustrated below (amounts in thousands, except per share data):

 

		Three months ended October 31
		2003			2002
Net earnings, as reported		$	319,256		$	482,564
Deduct:  Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects					(23,544		)
Pro forma net earnings		$	319,256		$	459,020
Earnings per share:
Basic, as reported		$	0.04		$	0.06
Basic, pro forma		$	0.04		$	0.06
Diluted, as reported		$	0.04		$	0.06
Diluted, pro forma		$	0.04		$	0.06

 

(6)                                 Subsequent Events- The Company acquired certain assets of Wood Protection Products, Inc. (“WPP”) effective as of December 5, 2003.  The purchase is being largely financed by a $6 million senior credit facility from SouthTrust Bank plus the issuance of an option to acquire 175,000 shares of the common stock, $0.01 par value, of the Company exercisable at $2.50 per share.  WPP is a distributor of pentachlorophenol (“penta”) solutions, which are used by wood treaters to treat utility poles.   Penta protects the utility poles from attack by mold, mildew, fungus, and insects.  The acquisition includes WPP’s distribution and plant equipment along with its inventory and product registrations and a consulting agreement with its principal shareholder.

 

9

 

 

ITEM 2.                                                     MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Results of Operations

 

The following table sets forth the Company’s net sales and certain other financial data, including the amount of the change between the three month periods ended October 31, 2003 and 2002:

 

		Three Months Ended October 31
		2003			2002
Net sales		$	8,372,110		$	8,053,629
Gross profit		$	2,546,204		$	2,716,351
Gross profit as a percent of net sales		30.4		%	33.7		%
Net income		$	319,256		$	482,564
Basic earnings per share		$	0.04		$	0.06
Weighted average shares outstanding		7,523,448			7,512,981

 

Sales Revenue and Gross Profit

 

Net sales revenue for the first quarter of fiscal 2004 increased 4% as compared with the first quarter of fiscal 2003.  However, more than half of the of the increase was due to sales of Rabon products, a product category not acquired by the Company until the second quarter of last fiscal year.  Net sales revenue from the Company’s pentachlorophenol (“penta”) wood treating chemical was improved over the same period of the prior fiscal year but the Company’s creosote product sales declined in the first quarter of fiscal 2003.  The Company’s penta products are used principally to treat utility poles and its creosote product is used to treat railroad crossties.  Penta results benefited from the price increase in June 2003 and from a modest rise in sales volume but the Company’s creosote sales continued to suffer from a supply shortfall in the northeast United States and because certain railroads specified creosote and oil treating blends as a cost containment measure.  Net sales revenue from the Company’s agricultural chemical products were down but sales of the products are heavily concentrated in the last fiscal quarter during the growing season of the crops to which the products are applied.

 

Gross profit as a percent of sales in the quarter declined to 30.4% for the first quarter of this fiscal year from 33.7% for the same quarter of fiscal 2003 because the Company experienced higher raw material costs and higher creosote purchase costs.  Raw material costs, which reached a peak in the fourth quarter of fiscal 2003, moderated somewhat in the first quarter.  However, the Company expects those increased costs will affect gross margins adversely over rest of the fiscal year.

 

10

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the first quarter of fiscal 2004 were approximately 4.6% higher than in the same quarter of the prior fiscal year.  The increase is due to selling, distribution and regulatory costs associated with the Company’s newly acquired Rabon product category.

 

Liquidity and Capital Resources

 

The principal balance of the Company’s term loan facility with SouthTrust Bank (“SouthTrust”) was approximately $4.6 million as of October 31, 2003, an increase of $3.3 million over the prior year.  The Company’s purchase for $3.8 million of the Rabon product category was the cause of that increase since the purchase was provided for by a refinance of the Company’s existing term loan facility with that bank.  The principal amount of the loan is being amortized monthly over ten years but the maturity date is December 20, 2007.  The loan carries interest at a varying rate equal to LIBOR plus 1.8%.  However, in February 2003, the Company entered into an interest rate swap transaction with SouthTrust which effectively fixed the interest rate at 5.0% for the remainder of the term.  Also as of October 31, 2003 the Company had no borrowings under its revolving loan with SouthTrust and its borrowing base availability under that loan was $3.5 million.  Management believes that the term loan and the revolving credit facility adequately provide for the Company’s anticipated need for liquidity and capital resources in fiscal 2004 for the Company’s current operations.

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements.

 

Disclosure Regarding Forward Looking Statements

 

Certain information included or incorporated by reference in this report is forward-looking, including statements contained in “Management’s Discussion and Analysis of Operations.”  It includes statements regarding the intent, belief and current expectations of the Company and its directors and officers.  Forward-looking information involves important risks and uncertainties that could materially alter results in the future from those expressed in these statements.   These risks and uncertainties include, but are not limited to, the ability of the Company to maintain existing relationships with long-standing customers, the ability of the Company to successfully implement productivity improvements, cost reduction initiatives, facilities expansion and the ability of the Company to develop,  market and sell new products include uncertainties relating to economic conditions, acquisitions and divestitures, government and regulatory policies, technological developments and changes in the competitive environment in which the Company operates.  Persons reading this report are cautioned that such statements are only predictions and actual events or results may differ materially.  In evaluating such statements, readers should specifically consider the various factors that could cause actual events or results to differ materially from those indicated by the forward-looking statements.

 

11

 

New Accounting Rules

 

Effective August 1, 2002, the Company adopted a statement promulgated by the Financial Accounting Standards Board (“FASB”), Statement of Financial Accounting Standards (“SFAS”) No. 142 “Goodwill and Other Intangible Assets.”  As a result, amortization expense decreased by approximately $23,000 per month.  See Note 1 to the “Notes to Condensed Consolidated Financial Statements.”

 

In February 2003, SFAS No. 148 was issued, “Accounting for Stock Based Compensation:  A Comparison of FASB Statement No. 123, Accounting for Stock-Based Compensation, and Its Related Interpretations, and IASB Proposed IFRS, Share-based Payments.”  SFAS No. 148 amends SFAS No. 123 to provide alternative methods of transition for an entity that voluntarily changes to the fair value based method of accounting for stock-based employee compensation.  It also amends the disclosure provisions of that Statement to require prominent disclosure about the effects on reported net income of an entity’s accounting policy decisions with respect to stock-based compensation.  The Company has chosen not to voluntarily change to the fair value based method of accounting for stock-based employee compensation but has adopted the disclosure rules of SFAS No. 148.

 

The Company has adopted SFAS No. 149, “Amendment of Statement 133 on Derivative Instruments and Hedging Activities.” The adoption of SFAS No. 149 did not have an impact on the Company’s financial position or results of operations.

 

The Company has adopted SFAS No. 150 “Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity.” This statement requires issuers to classify a financial instrument that is within its scope as a liability instead of equity.  The adoption of SFAS No. 150 did not have an impact on the Company’s financial position or results of operations.

 

Critical Accounting Policies

 

The Company’s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America.  The preparation of these financial statements requires the use of estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented.  The significant accounting principles that we believe are the most important to aid in fully understanding our financial results are the following:

 

Revenue Recognition – The Company essentially has only one revenue recognition transaction in which the Company’s chemical products sold in the open market are recognized as revenue as risk of loss and title to the products transfer to customers, which usually occurs at the time a shipment is made.

 

Allowance for Doubtful Accounts - The Company provides an allowance for accounts receivable it believes it may not collect in full.  A provision for bad debt expense recorded to selling, general and administrative expenses increases the allowance.  Accounts receivable that are written off the Company’s books decrease the allowance.  The amount of bad debt expense recorded each period and the resulting adequacy of the allowance at the end of each period are determined using a combination of the Company’s historical loss experience, customer-by-customer analyses of the Company’s accounts receivable balances each period and subjective assessments of the Company’s future bad debt exposure.

 

Inventories - - Inventories consist primarily of raw materials and finished goods that the Company holds for sale in the ordinary course of business.  It uses the first-in, first-out method to value inventories at the lower of cost or market.   Management believes the Company has not incurred impairments in the carrying value of its inventories.

 

12

 

Impairment of Long-lived Assets - The Company periodically reviews the carrying value of its long-lived assets held and used and assets to be disposed of, including supply contracts and other intangible assets, at least annually or when events and circumstances warrant such a review.  The carrying value of long-lived assets are evaluated for potential impairment on a product line basis.  The Company has concluded on the basis of its evaluation that the long lived assets are not impaired.

 

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

The Company is exposed to certain market risks arising from transactions that are entered into in the ordinary course of business, primarily from changes in foreign exchange rates.  The Company generally does not utilize derivative financial instruments or hedging transactions to manage that risk.  However, the Company did enter into an interest rate swap transaction in February, 2003 that effectively fixed the interest rate on its term loan at 5.0% for the remainder of the loan’s term.  An increase or decrease in interest rates would not affect the Company’s earnings or cash flow over the life of the term loan because the interest rate swap serves to fix the interest rate at 5.0%.   Should the financial market’s expectations for interest rates in the future increase then the value of the swap, recorded as an asset on the consolidated balance sheets, would increase.  Conversely, a drop in the financial market’s expectations for future interest rates would cause a drop in the value of that recorded asset.  It is possible that the future expectations for interest rates could decline enough to cause the swap to be recorded no longer as an asset, but as a liability, until the swap expires.

 

ITEM 4.  CONTROLS AND PROCEDURES.

 

Within 90 days prior to the filing of this report, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), an evaluation of the effectiveness of the Company’s disclosure controls and procedures was performed.  Based on this evaluation, the CEO and CFO have concluded that the Company’s disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management of the Company on a timely basis in order to comply with the Company’s disclosure obligations under the Securities Exchange Act and the rules of the SEC.  There were no significant changes in the Company’s internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

 

PART II — OTHER INFORMATION

 

ITEM 1.  LEGAL PROCEEDINGS.

 

The Company is not a party to any material legal actions or proceedings, other than ordinary routine litigation incidental to the business, and it does not believe any such actions or proceedings will have a material adverse effect on its business, results of operations or financial position.

 

13

 

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

 

There were no votes of shareholders during the period covered by this report but the annual meeting of the shareholders of the Company was held on November 18, 2003.  At that meeting, the shareholders voted to elect all the nominees for director as follows:

 

 

The shareholders voted to approve an amendment to the Company’s 1996 Stock Option Plan.  The amendment increased the number of shares of common stock that may be purchased under options granted under the plan by 700,000 shares.  The vote was 6,655,323 for the amendment, 32,240 against and 842 abstentions.  The shareholders also voted to ratify the appointment of Deloitte & Touche LLP as independent accountants and auditors of the Company for fiscal year 2004.  The vote was 6,953,686 votes for the ratification, 110 votes against and 1,113 abstentions.

 

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.

 

(a)                                  Exhibits:

 

The financial statements are filed as Part I of this report.  The following documents are filed as exhibits by the Company and documents marked by an asterisk (*) were previously filed (file number 29278):

 

2.1 (i)		First Amended Joint Plan of Reorganization dated September 1, 1995, as modified and clarified to date.*
2.1 (ii)		Asset Purchase and Sale Agreement dated June 26, 1998 with AlliedSignal, Inc.*
2.1 (iii)		Asset Sale Agreement dated October 3, 2000 between the Company and GB Biosciences Corporation*
2.1 (iv)		Asset Purchase Agreement dated December 30, 2002 between Boehringer Ingelheim Vetmedica, Inc. and KMG-Bernuth, Inc.*
2.2		Stock Exchange Agreement dated September 13, 1996 by and between W.P. Acquisition Corp., Halter Financial Group, Inc., KMG-Bernuth, Inc. and certain shareholders of KMG-Bernuth, Inc.*

 

14

 

3 (i)		Amended and Restated Articles of Incorporation.*
3 (ii)		Bylaws.*
3 (iii)		Articles of Amendment to Restated and Amended Articles of Incorporation, filed December 11, 1997.*
4.1		Form of Common Stock Certificate.*
10.1		Agency Agreement dated January 1, 1987 by and between Bernuth, Lembcke Co. Inc. and VfT AG.*
10.2		Revolving Loan Agreement dated August 1, 1996 by and between KMG-Bernuth, Inc. and SouthTrust Bank of Alabama, National Association.*
10.3		$2,500,000 Revolving Note dated August 1, 1996 payable by KMG-Bernuth, Inc. to SouthTrust Bank of Alabama, National Association.*
10.4		1996 Stock Option Plan.*
10.5		Stock Option Agreement dated October 17, 1996 by and between KMG-B, Inc. and Thomas H. Mitchell.*
10.6		Consulting Agreement dated October 15, 1996 by and between the Company and Gilman Financial Corporation.*
10.7		Split Dollar Insurance Agreement dated November 8, 1991 between KMG-Bernuth, Inc. and David L. Hatcher.*
10.8		Split Dollar Insurance Agreement dated December 13, 1991 between KMG-Bernuth, Inc. and Bobby D. Godfrey.*
10.9		Second Amendment to Revolving Loan Agreement.*
10.10		$2,500,000 Amended and Restated Revolving Note.*
10.11		Third Amendment to Revolving Loan Agreement.*
10.12		$2,500,000 Amended and Restated Revolving Note dated December 31, 1997.*
10.13		Employment Agreement dated February 1, 1998 with Bobby D. Godfrey.*
10.14		Creosote Supply Agreement dated as of June 30, 1998 between AlliedSignal Inc. and the Company.*
10.15		Performance Guaranty dated June 30, 1998 by the Company.*
10.16		Term Loan Agreement between SouthTrust Bank, National Association and KMG-Bernuth, Inc.*
10.17		$6,000,000 Term Note.*
10.18		Guaranty of Payment by the Company.*
10.19		Fourth Amendment to Revolving Loan Agreement.*
10.20		Creosote Supply Agreement dated November 1, 1998 between Rütgers VFT and the Company*
10.21		Option to Purchase 40,000 Shares of Common Stock dated as of September 16, 1998 between the Company and Halter Financial Group, Inc.*
10.22		Warrant for the Purchase of 25,000 Shares of Common Stock dated as of March 17, 1999 between the Company and JP Turner & Company, L.L.C.*
10.23		Manufacturing and Formulation Agreement dated October 3, 2000 between the Company and GB Biosciences Corporation.*
10.24		Warrant for the Purchase of 25,000 Shares of Common Stock dated as of March 6, 2000 between the Company and JGIS, Ltd., an assignee of Gilman Financial Corporation.*
10.25		Employment Agreement with Thomas H. Mitchell dated July 11, 2001.*
10.26		Employment Agreement with John V. Sobchak dated June 26, 2001.*
10.27		Supplemental Executive Retirement Plan dated effective August 1, 2001.*
10.28		Sales Agreement dated January 1, 2002 between Reilly Industries, Inc. and the Company.*

 

15

 

10.29		Contract Manufacturing Agreement dated December 30, 2002 between Boehringer Ingelheim Vetmedica, Inc. and KMG-Bernuth, Inc.*
10.30		Amended and Restated Promissory Note dated December 30, 2002 made payable by KMG-Bernuth, Inc. to SouthTrust Bank.*
10.31		Employment Agreement with Roger C. Jackson dated August 1, 2002.*
21.1		Subsidiaries of the Company.*
31		Certificates under Section 302 the Sarbanes-Oxley Act of 2002 of David L. Hatcher and John V. Sobchak pertaining to this report
32		Certificates under Section 906 of the Sarbanes-Oxley Act of 2002 of David L. Hatcher and John V. Sobchak pertaining to this report
99.1		Direct Stock Purchase Plan.*

 

16

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

KMG Chemicals, Inc.

 

 

By:	/s/ David L. Hatcher		Date:    December 15, 2003
	David L. Hatcher, President
By:	/s/ John V. Sobchak		Date:    December 15, 2003
	John V. Sobchak, Chief Financial Officer